Accelsius' MR250, the company’s first row-based Coolant Distribution Unit (CDU) and the latest advancement in scaling two-phase, direct-to-chip (2P D2C) liquid cooling for AI and high-performance ...
Oxford Drug Design’s lead compound demonstrated statistically significant anti-tumour activity with efficacy comparable to that of rapamycin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback